series-a
Stage
1
Investors
About
A-Alpha Bio develops a proprietary platform, AlphaSeq, that uses synthetic biology and machine learning to experimentally measure and predict millions of protein-protein interaction affinities at scale to accelerate therapeutic discovery.
Explore A-Alpha Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.